BioLineRX Ltd. (IL:BLRX)
TASE:BLRX
Want to see IL:BLRX full AI Analyst Report?
Top Page
Bioline Rx
(TASE:BLRX)
Select Model
Select Model
Rating:51Neutral
Price Target:
1.50
▲(0.00% Upside)
Action:Reiterated
Date:06/08/26
The score is held back primarily by heavy losses and ongoing cash burn with a limited runway, despite improving revenue/royalty momentum. Technicals are moderately constructive and the earnings call showed credible pipeline progress and early commercial traction, but valuation support is weak due to negative earnings and no dividend.
Positive Factors
Royalty revenue growth (APHEXDA)
Growing APHEXDA sales generating recurring royalty income validates third‑party commercialization and creates a non‑dilutive revenue stream. Consistent royalty receipts diversify funding beyond milestones, provide durable partial funding for operations, and increase optionality for partnering or reinvestment over the next several quarters.
Negative Factors
Negative operating and free cash flow
Sustained negative operating and free cash flow means the business cannot self‑fund development, forcing reliance on external financing or partner payments. Over months this increases dilution risk, constrains strategic choices, and could delay programs if capital markets or partner payments are unavailable.
Read all positive and negative factors
Positive Factors
Negative Factors
Royalty revenue growth (APHEXDA)
Growing APHEXDA sales generating recurring royalty income validates third‑party commercialization and creates a non‑dilutive revenue stream. Consistent royalty receipts diversify funding beyond milestones, provide durable partial funding for operations, and increase optionality for partnering or reinvestment over the next several quarters.
Read all positive factors
Bioline Rx (BLRX) vs. iShares MSCI Israel ETF (EIS)
Market Cap
₪41.94M
Dividend YieldN/A
Average Volume (3M)4.64M
Price to Earnings (P/E)―
Beta (1Y)0.48
Revenue Growth-94.40%
EPS Growth31.61%
CountryIL
Employees28
SectorHealthcare
Sector Strength45
IndustryBiotechnology
Share Statistics
EPS (TTM)>-0.01
Shares Outstanding2,620,977,300
10 Day Avg. Volume5,813,402
30 Day Avg. Volume4,637,561
Financial Highlights & Ratios
PEG Ratio0.10
Price to Book (P/B)0.68
Price to Sales (P/S)9.69
P/FCF Ratio-1.41
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)>-0.01
Revenue Forecast (FY)₪1.72M
Bioline Rx Business Overview & Revenue Model
Company Description
BioLineRx Ltd., an Israeli biopharmaceutical company founded in 2003 and headquartered in Hevel Modi'in, focuses its clinical development entirely on oncology. A pivotal asset in its pipeline is Motixafortide, a peptide that has successfully concl...
How the Company Makes Money
BioLineRx primarily makes money through (1) collaboration and licensing arrangements and (2) product-related revenue where it has commercialization rights. Under collaboration/licensing deals, the company may receive upfront payments, milestone pa...
Bioline Rx Earnings Call Summary
Earnings Call Date:May 27, 2026
(Q1-2026)
| % Change Since: |
Next Earnings Date:Aug 13, 2026
Earnings Call Sentiment Neutral
The call balanced meaningful scientific and clinical progress with clear commercial traction on APHEXDA and the strategic advancement of GLIX1 into first‑in‑human studies. These operational and scientific milestones are offset by weaker financial results versus the prior year — a swing from net income to net loss, a large decrease in nonoperating income, increased R&D spending and a limited cash runway into H1 2027. Management signaled optimism on pipeline progress and enrollment but provided limited disclosure on operational specifics (doses, site activations, Ayrmid commercialization details). Overall, the update reflects positive programmatic momentum but near‑term financial constraints and some executional/visibility risks.Positive Updates
GLIX1 First‑In‑Human Trial Initiated and First Patient Dosed
Phase I/IIa first‑in‑human trial of GLIX1 for glioblastoma (GBM) initiated; first patient dosed at NYU Langone. Trial Phase I expected to recruit up to 30 recurrent GBM/high‑grade glioma patients to establish MTD/recommended dose based on safety, PK/PD and preliminary efficacy. Periodic updates planned in H2 2026 with full dose escalation results expected in 2027.
Negative Updates
Quarterly Net Loss vs Prior Year Net Income
Net loss for Q1 2026 was $2.6M compared with net income of $5.1M in Q1 2025 — a swing of $7.7M from profit to loss for the quarter.
Read all updates
Q1-2026 Updates
Positive
Negative
GLIX1 First‑In‑Human Trial Initiated and First Patient Dosed
Phase I/IIa first‑in‑human trial of GLIX1 for glioblastoma (GBM) initiated; first patient dosed at NYU Langone. Trial Phase I expected to recruit up to 30 recurrent GBM/high‑grade glioma patients to establish MTD/recommended dose based on safety, PK/PD and preliminary efficacy. Periodic updates planned in H2 2026 with full dose escalation results expected in 2027.
Read all positive updates
Company Guidance
The call provided both near-term clinical timelines and detailed Q1 financials: GLIX1 has dosing underway at 3 academic centers (NYU, Northwestern, Moffitt) with the Phase I dose‑escalation expected to recruit up to 30 recurrent/high‑grade glioma patients, periodic updates planned in H2 2026 and full dose‑escalation results expected in 2027; CheMo4METPANC has a prespecified interim futility analysis when 40% of PFS events are observed (anticipated later this year); Q1 revenues were $0.5M (up $0.2M vs. $0.3M), R&D expense $2.5M (up $0.9M vs. $1.6M) driven by GLIX1, G&A $0.9M (down $0.1M vs. $1.0M), net non‑operating income $0.5M (vs. $7.6M prior year), net loss $2.6M (vs. net income $5.1M prior year), and cash and equivalents of $17.4M, which management said funds operations into the first half of 2027; commercial and preclinical metrics cited included APHEXDA sales of $2.5M in Q1 2026 (vs. $1.4M in Q1 2025) yielding $0.5M in royalty revenue to BioLineRx, GLIX1 efficacy in multiple CDx and temozolomide‑resistant PDX models, a tox safety margin (rat exposures up to 2,000 mg/kg), GBM median survival ~12–18 months, projected 2030 incidence ~18,500 U.S. and ~13,500 EU4+1 patients, and a U.S./Europe addressable market >$3.7 billion.Bioline Rx Financial Statement Overview
Summary
Income Statement
32
Negative
Balance Sheet
54
Neutral
Cash Flow
28
Negative
| Breakdown | TTM | Dec 2025 | Mar 2025 | Dec 2023 | Dec 2022 | Dec 2021 |
|---|---|---|---|---|---|---|
Income Statement | ||||||
| Total Revenue | 1.41M | 1.28M | 28.94M | 4.80M | 0.00 | 0.00 |
| Gross Profit | 1.05M | 462.21K | 19.68M | 1.11M | 0.00 | 0.00 |
| EBITDA | -11.25M | -10.57M | 3.92M | -57.09M | -28.50M | -24.07M |
| Net Income | -8.91M | -1.27M | -9.22M | -60.61M | -20.75M | -28.14M |
Balance Sheet | ||||||
| Total Assets | 38.80M | 40.91M | 38.91M | 63.92M | 76.38M | 81.39M |
| Cash, Cash Equivalents and Short-Term Investments | 17.35M | 20.88M | 19.56M | 42.99M | 51.08M | 57.13M |
| Total Debt | 9.07M | 10.15M | 15.04M | 11.59M | 12.32M | 4.65M |
| Total Liabilities | 18.14M | 17.56M | 25.45M | 50.70M | 25.54M | 13.30M |
| Stockholders Equity | 16.83M | 18.20M | 13.46M | 13.22M | 50.84M | 68.09M |
Cash Flow | ||||||
| Free Cash Flow | -7.96M | -8.77M | -43.93M | -22.91M | -26.56M | -23.67M |
| Operating Cash Flow | -7.93M | -8.74M | -43.87M | -22.61M | -26.24M | -23.57M |
| Investing Cash Flow | 2.48M | -9.25M | 29.37M | 1.44M | 4.01M | -38.22M |
| Financing Cash Flow | -2.06M | 9.62M | 20.66M | 15.06M | 20.44M | 57.75M |
Bioline Rx Technical Analysis
Positive
1.50
Price Trends
1.42
Positive
1.46
Positive
1.69
Negative
Market Momentum
0.03
Positive
54.91
Neutral
33.33
Neutral
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For IL:BLRX, the sentiment is Positive. The current price of 1.5 is below the 20-day moving average (MA) of 1.51, above the 50-day MA of 1.42, and below the 200-day MA of 1.69, indicating a neutral trend. The MACD of 0.03 indicates Positive momentum. The RSI at 54.91 is Neutral, neither overbought nor oversold. The STOCH value of 33.33 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Positive sentiment for IL:BLRX.
Bioline Rx Risk Analysis
Bioline Rx disclosed 43 risk factors in its most recent earnings report. Bioline Rx reported the most risks in the "Tech & Innovation" category.
Finance & Corporate - Financial and accounting risks. Risks related to the execution of corporate activity and strategy
Latest Risks Added 0 New Risks
Bioline Rx Peers Comparison
UnderperformOutperform
Sector (51)
IL:BLRX
Bioline Rx
1.60
-1.30
-44.83%
IL:XTLB
Xtl Bio
1.70
-2.40
-58.54%
IL:CBI
Clal Biotech
26.60
-3.30
-11.04%
IL:CANF
Can Fite Bio
424.30
423.00
32538.46%
IL:BOLT
Biolight
292.90
-246.00
-45.65%
Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.